Xtant Medical Holdings DB:XMS Stok Raporu Şirket Finansalları + 2 Analistler
Xtant Medical Holdings, Inc.
DB:XMS Stok Raporu
XMS Stoklara Genel Bakış Xtant Medical Holdings, Inc. ortopedik ve nörolojik cerrahlar için rejeneratif tıp ürünleri ve tıbbi cihazlar sağlamaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Xtant Medical Holdings, Inc. Rakipler Fiyat Geçmişi ve Performans
için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Xtant Medical Holdings Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$0.40 52 Haftanın En Yüksek Seviyesi US$1.28 52 Haftanın En Düşük Seviyesi US$0.36 Beta 0.38 11 Aylık Değişim -21.58% 3 Aylık Değişim -19.51% 1 Yıllık Değişim -62.99% 33 Yıllık Değişim -55.00% 5 Yıllık Değişim -75.71% Halka arzdan bu yana değişim -85.22%
Son Haberler & Güncellemeler
Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
New minor risk - Profitability Oct 18
Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System Sep 24
Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus Sep 18
New major risk - Share price stability Sep 05 Xtant Medical Holdings, Inc. announced that it has received $5 million in funding Aug 13
Daha fazla güncelleme görün
Xtant Medical Holdings, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 07
New minor risk - Profitability Oct 18
Xtant Medical Holdings, Inc. Expands Product Portfolio with the Launch of the Cortera(R) Posterior Fixation System Sep 24
Xtant Medical Holdings, Inc. Expands Product Portfolio with Launch of its Own Viable Bone Matrix, OsteoVive(R) Plus Sep 18
New major risk - Share price stability Sep 05 Xtant Medical Holdings, Inc. announced that it has received $5 million in funding Aug 13
New minor risk - Shareholder dilution Aug 11
Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.02 loss in 2Q 2023) Aug 09
Xtant Medical Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2024 Aug 09 Xtant Medical Holdings, Inc. to Report Q2, 2024 Results on Aug 08, 2024
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 23, 2024 Jun 13
New minor risk - Profitability Jun 07
New minor risk - Financial position May 17
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Full Year 2024 May 17
Xtant Medical Holdings, Inc. to Report Q1, 2024 Results on May 15, 2024 May 10
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds May 01
Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds Apr 30
Xtant Medical Holdings, Inc. Provides Earnings Guidance for the Full Year 2024 Apr 03
Full year 2023 earnings released: EPS: US$0.006 (vs US$0.09 loss in FY 2022) Apr 02
Xtant Medical Holdings, Inc. to Report Q4, 2023 Results on Apr 01, 2024 Mar 22
Investor sentiment improves as stock rises 23% Feb 29
Xtant Medical Holdings, Inc. Revises Earnings Guidance for the Year 2023 Nov 10
Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.025 loss in 3Q 2022) Nov 10
Xtant Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million. Oct 24
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA). Aug 12
Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023 Aug 03
Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.02 loss in 2Q 2022) Aug 02
Xtant Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 26 Xtant Medical Holdings, Inc. announced that it expects to receive $15 million in funding Jul 04
Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million. Jun 21
Xtant Medical Holdings, Inc. Appoints Lori Mitchell-Keller to Board of Directors May 19
First quarter 2023 earnings released: US$0.019 loss per share (vs US$0.025 loss in 1Q 2022) May 07
Xtant Medical Holdings, Inc. Announces Executive Changes May 06
Xtant Medical Holdings, Inc. Provides Revenue Guidance for the Full Year 2023 May 05
Full year 2022 earnings released: US$0.09 loss per share (vs US$0.057 loss in FY 2021) Mar 09
Xtant Medical Holdings, Inc., Annual General Meeting, Jul 26, 2023 Feb 02
Xtant Medical Holdings, Inc. Appoints Mark Schallenberger as Chief Operations Officer, Effective January 16, 2023 Jan 10
Less than half of directors are independent Nov 16
Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.021 loss in 3Q 2021) Nov 04
Xtant Medical Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 28
Xtant Medical Holdings, Inc., Annual General Meeting, Oct 26, 2022 Sep 01 Xtant Medical Holdings, Inc. announced that it expects to receive $9.746606 million in funding
Second quarter 2022 earnings released: US$0.02 loss per share (vs US$0.008 loss in 2Q 2021) Aug 05
Xtant Medical Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
First quarter 2022 earnings released: US$0.025 loss per share (vs US$0 in 1Q 2021) May 06
Xtant Medical Holdings, Inc. Announces the Appointment of Scott Neils as Chief Financial Officer, Effective June 1, 2022 May 03
Less than half of directors are independent Apr 27
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 09
Xtant Medical Holdings, Inc. to Report Q4, 2021 Results on Mar 08, 2022 Mar 03
Third quarter 2021 earnings released: US$0.021 loss per share (vs US$0.10 loss in 3Q 2020) Nov 13
Second quarter 2021 earnings released: US$0.008 loss per share (vs US$0.19 loss in 2Q 2020) Aug 09
Xtant Medical Holdings, Inc. announced that it has received $20.000003 million in funding Feb 26
Full year 2020 earnings released: US$0.25 loss per share (vs US$0.63 loss in FY 2019) Feb 25
Xtant Medical Holdings, Inc. announced that it expects to receive $20.000003 million in funding Feb 24
Xtant Medical Holdings, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 18
New 90-day high: €1.49 Feb 11
New 90-day high: €1.20 Jan 24
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue misses expectations Oct 30
Xtant Medical Holdings, Inc. Regains Compliance with NYSE American Continued Listing Standards Oct 07 Xtant Medical Holdings, Inc. announced that it expects to receive $62.882 million in funding
New 90-day low: €0.65 Sep 28
New 90-day low - €0.66 Sep 11
New 90-day low - €0.76 Aug 21
First half earnings released Aug 04
Xtant Medical Holdings, Inc. to Report Q2, 2020 Results on Aug 03, 2020 Jul 31
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Growth Index Jul 05
Xtant Medical Holdings, Inc.(AMEX:XTNT) dropped from Russell Microcap Index Jul 02 Hissedar Getirileri XMS DE Medical Equipment DE Pazar 7D 9.4% -2.4% -0.2% 1Y -63.0% -3.8% 7.8%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: XMS geçen yıl % -3.8 oranında getiri sağlayan German Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: XMS geçen yıl % 7.8 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is XMS's price volatile compared to industry and market? XMS volatility XMS Average Weekly Movement 13.6% Medical Equipment Industry Average Movement 5.0% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.7% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: XMS hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: XMS 'nin haftalık oynaklığı ( 14% ) geçen yıl boyunca sabit kaldı, ancak hala German hisselerinin %75'inden yüksek.
Şirket Hakkında Xtant Medical Holdings, Inc. ortopedik ve nörolojik cerrahlar için rejeneratif tıp ürünleri ve tıbbi cihazlar sağlamaktadır. Hücresel büyüme için doğal bir iskele sağlayan ve kemik oluşturan proteinleri iyileşme ortamına maruz bırakan OsteoSponge; herhangi bir şekle kalıplamak ve kemik boşluklarına sıkıştırmak için OsteoSelect DBM Putty; onaylanmış terminal sterilizasyon yoluyla kullanım özellikleri sunmak ve hasta güvenliğini sağlamak için OsteoSelect PLUS DBM Putty; osteokondüktiviteyi ve insan kemiğinin osteoindüktif potansiyelini en üst düzeye çıkaran bir allogreft ailesi olan 3Demin'i sunmaktadır; Allogreft kemiğin endosteum tabakasında bulunan tutulmuş büyüme faktörlerini içeren işlenmiş bir allogreft olan OsteoFactor; büyüme faktörü ile zenginleştirilmiş hücresel kemik matrisi olan OsteoVive Plus; ve osteokondüktif nano yapılı hidroksiapatit ve tasarlanmış bir hücre dışı matris biyoiskele kolajen taşıyıcı sağlayan nanOss ürün ailesi. Ayrıca, ön ve arka çapraz bağ onarımları, ön çapraz bağ rekonstrüksiyonu ve menisküs onarımı için spor allogreftleri; istenen şekil ve boyutlarda öğütülmüş kortikal kemik için öğütülmüş spinal allogreftler ve ortopedi, nöroloji, podiatri, oral / maksillofasiyal, genitoüriner ve plastik / rekonstrüktif uygulamalar için geleneksel allogreftler işlemekte ve dağıtmaktadır.
Daha fazla göster Xtant Medical Holdings, Inc. Temel Bilgiler Özeti Xtant Medical Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? XMS temel i̇stati̇sti̇kler Piyasa değeri €70.93m Kazançlar(TTM ) -€3.16m Gelir(TTM ) €105.06m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) XMS gelir tablosu (TTM ) Gelir US$110.94m Gelir Maliyeti US$42.59m Brüt Kâr US$68.36m Diğer Giderler US$71.69m Kazançlar -US$3.33m
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
